CBD and Lennox-Gastaut Syndrome
Pharmaceutical-grade cannabidiol reduces drop seizures in Lennox-Gastaut syndrome, with strong randomized trial evidence and a clear side-effect profile.
This is one of the few areas where cannabis-derived medicine has earned its place through proper randomized trials, not anecdote. Pharmaceutical CBD (Epidiolex/Epidyolex) genuinely cuts drop seizures in Lennox-Gastaut syndrome and is FDA- and EMA-approved for it. But 'CBD works for LGS' does not mean a bottle of hemp oil from a dispensary will. Dose, purity, and drug interactions matter a lot. Talk to a pediatric neurologist before changing anything.
Not Medical Advice
This article is not medical advice. Lennox-Gastaut syndrome is a severe, treatment-resistant childhood epilepsy. Any change to anticonvulsant therapy — adding CBD, adjusting clobazam, stopping valproate — must be made with a pediatric neurologist or epileptologist. Over-the-counter hemp CBD products are not equivalent to the prescription medication studied in the trials described below.
Plain-Language Summary
Lennox-Gastaut syndrome (LGS) is a rare, severe epilepsy that usually begins between ages 3 and 5. It causes multiple seizure types, especially drop attacks (tonic or atonic seizures that cause falls), along with cognitive impairment and an abnormal EEG pattern (slow spike-and-wave). Most children with LGS continue to have seizures despite multiple antiseizure medications.
Cannabidiol (CBD), the non-intoxicating cannabinoid from cannabis, has been formulated as a purified prescription drug called Epidiolex (Epidyolex in Europe). In randomized controlled trials, it reduced drop seizures by roughly 17–22 percentage points more than placebo when added to existing treatment [1][2] Strong evidence. The FDA approved it for LGS in June 2018 [3].
This is not a cure. It does not work for every child. Most patients still have seizures. But it is a real, measurable benefit backed by Phase III evidence — which is more than can be said for almost any other cannabis claim.
What Probably Works (Strong Evidence)
Reduction in drop seizures. Two pivotal Phase III randomized, double-blind, placebo-controlled trials (GWPCARE3 and GWPCARE4) tested add-on CBD in children and adults with LGS. In Devinsky et al. 2018 (NEJM), CBD 20 mg/kg/day reduced drop-seizure frequency by a median of 41.9% vs. 17.2% on placebo [1] Strong evidence. Thiele et al. 2018 (Lancet) found a 43.9% reduction with CBD vs. 21.8% with placebo [2] Strong evidence.
Reduction in total seizures. Both trials showed significant reductions in all-seizure frequency as a secondary endpoint [1][2] Strong evidence.
Sustained effect in open-label extension. Patients followed for up to ~2 years in the open-label extension generally maintained their seizure reduction, though some developed tolerance [4] Strong evidence.
Dose-response. A trial comparing 10 mg/kg/day vs. 20 mg/kg/day found both doses effective, with the lower dose offering a better tolerability profile [2] Strong evidence. Many clinicians titrate to effect rather than automatically pushing to 20 mg/kg/day.
What Might Work (Weak or Mixed Evidence)
Quality of life and caregiver burden. Secondary analyses suggest improvements, but these endpoints are subjective and were not the trials' primary focus Weak / limited.
Cognition and behavior. Some open-label reports describe improved alertness, but controlled data are limited and confounded by reductions in other sedating antiseizure drugs and by clobazam interactions Weak / limited.
Seizure freedom. Achieved by only a small minority of patients. LGS is largely a 'reduce frequency,' not 'cure,' condition Weak / limited.
Artisanal / hemp-derived CBD products. Case series and parent surveys exist, but product contents vary wildly, dosing is inconsistent, and several studies have found label inaccuracies in commercial CBD products [5] Weak / limited. Effect sizes in artisanal-CBD case reports cannot be cleanly attributed to CBD itself.
What Doesn't Work or Lacks Evidence
Smoked or vaporized cannabis flower for LGS. No controlled evidence. THC exposure in children is not appropriate and carries cognitive risks No data.
'Full-spectrum is always better than isolate.' Marketing claim. The drug with the strongest LGS evidence — Epidiolex — is highly purified CBD, not a full-spectrum product. The 'entourage effect' is plausible in some contexts but is not established for LGS Disputed.
CBD as monotherapy for LGS. Trials studied CBD as add-on therapy. There is no high-quality evidence supporting CBD alone for LGS No data.
Specific terpene profiles changing efficacy. No clinical data in LGS No data.
What We Don't Know
- Long-term (10+ year) safety in children, including effects on neurodevelopment and liver health.
- Whether the benefit in trials reflects CBD itself, or partly an interaction with clobazam (CBD raises levels of clobazam's active metabolite, N-desmethylclobazam) [6] Strong evidence. Sub-analyses suggest CBD still helps patients not on clobazam, but the effect size may be smaller Weak / limited.
- Which patients respond. There are no validated biomarkers or genetic predictors of response.
- Optimal dose in adults vs. children.
- Whether pharmaceutical CBD differs meaningfully from well-manufactured artisanal CBD at equivalent verified doses (under-studied).
Comparison With Standard LGS Treatments
LGS is treated with combinations of antiseizure medications. None reliably stop seizures. Commonly used agents include valproate, lamotrigine, rufinamide, topiramate, clobazam, felbamate, and the ketogenic diet; vagus nerve stimulation and corpus callosotomy are non-drug options [7] Strong evidence.
In the absence of head-to-head trials, indirect comparisons of placebo-controlled add-on trials suggest CBD's effect on drop seizures is roughly comparable to rufinamide and clobazam, and possibly greater than felbamate or lamotrigine — but these comparisons are not definitive [7] Weak / limited. CBD is generally added when 2–3 prior medications have failed. It does not replace existing therapy; it is layered on top.
Risks and Side Effects
Common adverse events in trials (≥10%, more than placebo): somnolence, decreased appetite, diarrhea, fatigue, and elevated liver enzymes (ALT/AST) [1][2] Strong evidence.
Liver enzyme elevations are dose-dependent and more frequent in patients also taking valproate. Periodic LFT monitoring is recommended, particularly in the first 6 months [3] Strong evidence.
Clobazam interaction. CBD inhibits CYP2C19, raising levels of N-desmethylclobazam. This can increase sedation and may contribute to seizure improvement. Clobazam dose reduction is often needed [6] Strong evidence.
Other interactions. CBD affects multiple CYP enzymes (3A4, 2C9, 2C19) and is itself metabolized by them. Interactions with warfarin, certain antidepressants, and other antiseizure drugs are possible [3] Strong evidence.
Suicidal ideation. Class warning for antiseizure medications applies.
Withdrawal. Like other antiseizure drugs, CBD should not be stopped abruptly; taper to reduce seizure risk.
Bottom Line
Pharmaceutical CBD is a legitimate, evidence-based add-on therapy for Lennox-Gastaut syndrome. It reduces drop seizures by a clinically meaningful amount on top of existing treatment. It is not a miracle, not a cure, and not interchangeable with over-the-counter hemp products. Decisions about starting, dosing, or combining it with other antiseizure drugs belong with a pediatric neurologist who can monitor liver function, drug levels, and interactions.
See also: CBD (cannabidiol), CBD and Dravet syndrome, Epidiolex, Cannabis–drug interactions.
Sources
- Peer-reviewed Devinsky O, Patel AD, Cross JH, et al. Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome. New England Journal of Medicine. 2018;378(20):1888–1897.
- Peer-reviewed Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 2018;391(10125):1085–1096.
- Government U.S. Food and Drug Administration. Epidiolex (cannabidiol) Prescribing Information. Updated label, FDA Drug Database. ↗
- Peer-reviewed Thiele E, Marsh E, Mazurkiewicz-Beldzinska M, et al. Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. Epilepsia. 2019;60(3):419–428.
- Peer-reviewed Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling Accuracy of Cannabidiol Extracts Sold Online. JAMA. 2017;318(17):1708–1709.
- Peer-reviewed Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246–1251.
- Peer-reviewed Cross JH, Auvin S, Falip M, Striano P, Arzimanoglou A. Expert Opinion on the Management of Lennox–Gastaut Syndrome: Treatment Algorithms and Practical Considerations. Frontiers in Neurology. 2017;8:505.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.